Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases using deep phenotyping, precision RNA medicine, and testing in live human donor livers. The company has generated spatial‑sequencing, single‑cell sequencing, and imaging data in over 1,000 diseased human livers across three continents. Ochre has launched 'Liver ICUs' across the US to test RNA‑based drug candidates directly in human livers. Proceeds from the Series A will be used to translate discovery research into RNA drug candidates and to fund human liver preclinical testing in 2023 to select therapies for clinical development in 2024. The company plans to broaden its discovery and development platforms, including a state‑of‑the‑art RNA chemistry platform and an exploratory platform to expand research into a wider set of liver diseases. Ochre's longer‑term goals include regenerating organs in patients and improving the viability of marginal donor livers to reduce the need for transplants. Ochre Bio develops RNA medicines for chronic liver diseases and uses deep phenotyping ('phenomics') to digitize liver biology at scale. The company has generated large amounts of spatial genomics data from freshly donated human livers and uncovered hundreds of novel potential liver targets that are being validated in their labs. By 2022, Ochre plans to build a complete in silico human liver of over 10^11 measurements to predict the effect of perturbing any gene in major liver cell types. In addition to computational work, Ochre tests therapeutics in explanted human livers maintained extracorporeally and has developed a full-stack GalNAc-siRNA development process validated in actively perfused human livers. Planned uses of recent funding include advancing RNA therapies, expanding the deep phenotyping platform, onboarding five transplant center partners to test therapies on discarded donor livers, and moving products toward clinical development; the company also opened a Taiwanese lab to study liver disease in Asia. Ochre is based in Oxford, England and is built on over 15 years of experience in liver genomics and advanced therapies.

Total raised

$40M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2022